CHARACTERISTICS OF A NEW ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR - DELAPRIL

被引：25

作者：

SARUTA, T

NISHIKAWA, K

机构：

[1] Department of Internal Medicine, Keio University School of Medicine, Tokyo

[2] Department of Internal Medicine, Keio University School of Medicine, Tokyo, 35, Shinano-machi, Shinjuku-ku

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1991年 / 4卷 / 01期

关键词：

ANGIOTENSIN CONVERTING ENZYME INHIBITOR; DELAPRIL; AORTIC ANGIOTENSIN CONVERTING ENZYME ACTIVITY; COUGH;

D O I：

10.1093/ajh/4.1.23S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Delapril, a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, which has an indanylglycine moiety differing from the proline moiety of captopril or enalapril, is an esterified prodrug that is converted in vivo to its active metabolites. Delapril effectively inhibits rabbit lung ACE activity and lowers blood pressure in spontaneously hypertensive rats. Delapril has several characteristics that differ from captopril and enalapril, including high lipophilicity and weak bradykinin potentiating action. Delapril is a more potent inhibitor of vascular wall ACE activity than enalapril or captopril. It also shows a weaker potentiating action on the citric acid-induced cough in the guinea pig model compared with captopril and enalapril. In 12 out of 150 patients with essential hypertension who complained of cough during treatment with enalapril, changing to delapril resulted in resolution of the cough in 6 out of 12 of these patients: the percentage of patients in the total population with cough decreased from 8% to 4%.

引用

页码：S23 / S28

页数：6

共 20 条

[1]

Bravo E.L., Tarazi R.C., Converting enzyme inhibition with an orally active compound in hypertensive man, Hypertension, 1, pp. 39-46, (1979)

[2]

Sweet C.S., Gross D.M., Arbegast P.T., Et al., Antihypertensive activity of N-[(S)-l-(ethoxycarbonyl)-3-phenylpro-pyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor, J Pharmacol Exp Ther, 216, pp. 558-566, (1981)

[3]

Wilkins L.H., Dustan H.P., Walker J.F., Et al., Enalapril in low-renin essential hypertension, Clin Pharmacol Ther, 43, pp. 297-302, (1983)

[4]

Cohen M.L., Kurz K.D., Angiotensin converting enzyme inhibition in tissue from spontaneously hypertensive rats after treatment with captopril or MK-421, J Pharmacol Exp Ther, 220, pp. 63-69, (1982)

[5]

Miyazaki M., Okunishi H., Nishimura K., Et al., Vascular angiotensin-converting enzyme activity in man and other species, Clin Sci, 66, pp. 39-45, (1984)

[6]

Miyake A., Itoh K., Oka Y., Design and synthesis of N-[N-[(S)-l-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-N-(indan-2-yl)glycine (CV-3317), a new potent angiotensin converting enzyme inhibitor, Chem Pharm Bull (Tokyo), 34, pp. 2852-2858, (1986)

[7]

Oka Y., Nishikawa K., Kito G., Et al., Delapril. Cardiovascular Drug Reviews, 6, pp. 192-205, (1988)

[8]

Miyake A., Itoh T., Aono S., Et al., Synthesis and angiotensin converting enzyme inhibitory activity of 1, 2, 3, 4-te-trahydroisoquinoline-3-carboxylic acid derivatives, J Ta-Keda Res Lab, 43, pp. 53-76, (1984)

[9]

Tsukamoto T., Yoshida K., Mitani M., Et al., Metabolic fate of delapril hydrochloride (CV-3317), a new angiotensin converting enzyme inhibitor, in rats and dogs, Jpn Pharmacol Ther, 15, pp. 1167-1193, (1987)

[10]

Yoshida K., Tsukamoto T., KobayashiT, etal: Pharmacokinetics and metabolism of delapril hydrochloride (CV-3317), a new angiotensin converting enzyme inhibitor, in rats and dogs, Jpn Pharmacol Ther, 13, pp. 7151-7165, (1985)

← 1 2 →